HomeSSKN • NASDAQ
add
STRATA Skin Sciences Inc
Previous close
$2.55
Year range
$2.51 - $5.90
Market cap
10.64M USD
Avg Volume
3.04K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 9.58M | 10.21% |
Operating expense | 6.12M | 2.77% |
Net income | -4.50M | -18.53% |
Net profit margin | -46.96 | -7.56% |
Earnings per share | 0.29 | 164.25% |
EBITDA | 864.00K | 608.20% |
Effective tax rate | 3.64% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 7.26M | 7.03% |
Total assets | 36.16M | -13.94% |
Total liabilities | 31.18M | 6.33% |
Total equity | 4.97M | — |
Shares outstanding | 4.17M | — |
Price to book | 2.14 | — |
Return on assets | -2.40% | — |
Return on capital | -3.87% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -4.50M | -18.53% |
Cash from operations | 703.00K | -48.72% |
Cash from investing | -504.00K | 70.66% |
Cash from financing | 0.00 | — |
Net change in cash | 199.00K | 157.35% |
Free cash flow | 481.38K | -83.68% |
About
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
The company's flagship product, XTRAC, is a medical device that allows for a trained dermatologist to treat skin conditions like Vitiligo and Psoriasis with monochromatic UV Light. Following completion of a successful conformity assessment procedure, Strata Skin Sciences has also been granted CE Mark approval for sale of MelaFind in the European Union.
In July 2015, the company acquired PhotoMedex Inc. and is planning to relocate its headquarters from Irvington, New York to Horsham, Pennsylvania in Montgomery County. Wikipedia
Founded
Jan 1, 1989
Headquarters
Website
Employees
106
